Field report SW-12 / M4 · sheet /strategy
Corporate StrategyFiled from the territory
Oracle Reclaims $118 After $20B Raise, Chart Targets $170 and $329
Oracle closed at $117.91 on Nov 10 after a $20B raise at $116, with a $664B backlog, negative FY26 free cash flow and a $236 average analyst target.
- Grid
- SW-12 / M4
- Surveyed
- November 17, 2026
- Reading
- 4 min read
- Correspondent
- Olivia Hart

Field notes
- Oracle closed at $117.91 on Nov 10, 2026, up 1.56%, after a $20B raise priced at $116 on Nov 2-4
- Remaining performance obligations reached $664B; Q1 FY27 revenue was $19.35B, up 29.6% YoY
- Investor Day (Oct 28, 2026) guided FY30 revenue above $225B and non-GAAP EPS above $21; shares rose ~11%
- Free cash flow stayed negative in FY26 on $55.7B capex; positive FCF targeted for H2 FY28
- Average analyst target is $236 (~+100%); technical targets stand at $170 and $329
By Olivia Hart
Oracle closed at $117.91 on November 10, up 1.56%, recovering the $118 level just days after a $20 billion capital raise briefly dragged the stock into the low $110s. The rebound puts the stock back in its post-Investor-Day range, with technical targets of $170 and $329 on the daily and weekly charts.
For practitioners, the story is a race between cash burn and contracted revenue. Here is what each piece changes.
Why did the stock move?
Three events set the current price. The first came at Investor Day on October 28, 2026, when Oracle guided to FY30 revenue above $225 billion — a compound annual growth rate of 35% or more from FY26 — and non-GAAP EPS above $21. Management committed to positive free cash flow in the second half of FY28 and $30 billion or more in FY29, and capped future capital raises at $20 billion through FY30. Shares ripped roughly 11% that day.
The second came on September 10, 2026, with the Q1 FY27 report. Revenue reached $19.35 billion, up 29.6% year over year. Non-GAAP EPS of $1.92 beat the $1.74 consensus. Remaining performance obligations hit $664 billion, with cloud infrastructure driving the growth.
The third event tested conviction. Between November 2 and 4, 2026, Oracle sold 86.2 million shares at $116 and issued $10 billion of notes, raising net proceeds of about $20 billion and exhausting the self-imposed cap through FY30. The stock tested the low $110s before rebounding.
What do the multiples say?
Oracle now trades at roughly 14x forward earnings against a trailing P/E of about 18.8. The bull case rests on the gap to history: the stock has averaged near 21x over multiple years, measured against forward FY27 non-GAAP EPS of $8.10. On that math, the compression implies significant re-rating room if management delivers its Investor Day path.
The Street agrees, at least on paper. The average analyst target sits at $236, roughly 100% above the current price, and aligns with the long-term revenue and margin trajectory laid out on October 28.
Who owns the register?
Institutional concentration frames how the raise was absorbed:
- BlackRock holds 145.35 million shares, a 5.05% stake
- Vanguard Capital Management holds 111.79 million shares, or 3.88%
- State Street holds 78.65 million shares, or 2.73%
- Insiders own roughly 38% of the company
That insider ownership near 38% matters for practitioners watching dilution. The 86.2 million new shares went to market at $116, and the stock recovered the $118 level within a week — evidence that demand absorbed the supply without a sustained break lower.
What is the cash story?
The core tension is capex against backlog. Oracle is funding a massive AI cloud build with heavy near-term capital spending while remaining performance obligations sit at $664 billion. Free cash flow stayed negative in FY26 on $55.7 billion of capex. Management targets positive free cash flow in the second half of FY28 and self-funding from FY29, with free cash flow exceeding $30 billion in FY29.
With the $20 billion cap now exhausted, the company has closed off further equity issuance through FY30. Any capex overrun beyond internal cash generation would have to come from debt markets or from hitting the FY29 self-funding target on schedule. That makes the December earnings print a checkpoint on the credibility of the whole timeline.
What comes next?
Two dates anchor the near term. Oracle reports Q2 FY27 earnings on December 14, 2026 — the next catalyst for the equity. The annual meeting follows on November 18, 2026.
The chart work, published by TradingView analyst StockWhaleX, frames the setup in three levels:
- Entry: the $117–120 zone
- Target 1: $170, a gain of about 44%
- Target 2: $329
The analyst's read is that daily and weekly charts show a completed corrective structure, which supports the measured move targets. The title of the analysis itself notes the sequence: the chart eyes $170, then $329.
What should practitioners take from it?
The decision, stripped to its elements: Oracle trades at roughly half its average multiple, carries a $664 billion contracted backlog, and has just exhausted its self-imposed $20 billion raise cap. Against that, free cash flow remains negative after $55.7 billion of FY26 capex, and the positive-FCF promise does not arrive until the second half of FY28.
The comparison that frames the trade: at 14x forward earnings, Oracle is priced as a slow grower while reporting 29.6% revenue growth and guiding to a 35%+ CAGR through FY30. Whether that gap closes depends on the December 14 report and the November 18 meeting confirming the timeline, not on the chart.
The technicals give the entry and the targets. The fundamentals give the deadlines.
via tradingview.com (Source)
More from Olivia Hart
Show full bio
News editor covering regulation, policy and their impact on corporate strategy and chief-executive leadership at CEO Frontier.
458 articles